Founded in May 2017 and based at the Babraham Research Campus in Cambridge, PredictImmune develops pioneering tools for guiding treatment options in immune-mediated inflammatory diseases like Crohn’s and ulcerative colitis (IBD).
Based on ten years of research at Cambridge University, PredictImmune’s test kits help both clinicians and patients to understand, at the point of diagnosis, the likely course of disease and opens the possibility of better treatment choices from the outset.
Business funding insights
A decade of hard work coming to fruition? Just look at our investments and exits
Far from slowing down as a result of the coronavirus pandemic, BGF’s investment activity has stepped up both in pace and volume.
Exit strategies: how to get the timing and valuation right
More than 100 BGF-backed businesses have achieved exits. Our panel of experts discuss the exit strategies that are proven to succeed.